These studies suggest that germline BAP1 mutations may orchestrate a metastatic OM program and that transmission of deleterious alleles may engender a mixed CM-OM pedigree, which could serve as a clinical marker of constitutive BAP1 loss. This evidence concerns the gene BAP1 and cutaneous mastocytosis.